Olanzapine News and Research

RSS

Olanzapine (trade names Zyprexa, Zyprexa Zydis, Zalasta, Zolafren, Olzapin, Rexapin or in combination with fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for the treatment of schizophrenia and bipolar disorder.

Spectral Modeling technology substantiated through creation of antipsychotic bank of drug candidates

LIUS Molecular Design is pleased to announce that it has successfully created two antipsychotic drug candidates with third party confirmation of predicted biological activities via in vitro testing.

19 May 2008

Treatment with an anti-psychotic drug found to cause changes in metabolism earlier than expected

Schizophrenia is a complex type of psychotic mental illness characterized by thoughts that are uncoupled from reality.

8 Apr 2008

Aripiprazole has potential for treating alcohol dependence

Aripiprazole is currently approved to treat bipolar disorder as well as schizophrenia. A new study has found that it significantly and dose-dependently increases the sedative effects of alcohol and, to a lesser degree, decreases the euphoric effects of alcohol. Future research will need to examine the beneficial versus the side effects of aripiprazole for treatment of alcohol dependence.

4 Apr 2008

Lilly knocked back by FDA on Zyprexa for schizophrenia treatment

Eli Lilly and Company has received a not approvable letter from the U.S. Food and Drug Administration for Zyprexa long-acting injection (olanzapine LAI) for the treatment and maintenance treatment of schizophrenia in adults, the company announced.

28 Feb 2008

Treatment of children and adolescents with schizophrenia

There is a wealth of scientific literature available on the treatment of adults diagnosed with schizophrenia.

28 Feb 2008

New schizophrenia treatment

Schizophrenia is one of the most debilitating of the major psychiatric disorders, and is also one of the most difficult to treat.

14 Dec 2007

Novel and inexpensive tool for identifying early signs of schizophrenia

A tendency to extract messages from meaningless noise could be an early sign of schizophrenia, according to a study by Yale School of Medicine researchers.

24 Oct 2007

Little evidence to support therapies for post-traumatic stress disorder

Post-traumatic stress disorder (PTSD) is a severe and ongoing emotional reaction to an extreme psychological trauma; it affects significant numbers of people, in particular military personnel and veterans, who have seen active duty in war zones.

22 Oct 2007

Review of PTSD treatments

Many people, including significant proportions of active duty military personnel and veterans, suffer from post-traumatic stress disorder (PTSD), often in conjunction with other injuries or illnesses.

19 Oct 2007

Urgent need for better understanding of bipolar disease in children and adolescents

The number of visits to a doctor's office that resulted in a diagnosis of bipolar disorder in children and adolescents has increased by 40 times over the last decade, reported researchers funded in part by the National Institutes of Health (NIH).

4 Sep 2007

New and very different schizophrenia drug shows promise

Scientists at Eli Lilly say the first human trial of a new schizophrenia drug shows promise for sufferers of the debilitating mental illness.

3 Sep 2007

New treatments for migraines and chronic headaches

Twelve percent of the population, three quarters of them women, suffer at least occasionally from migraines and about 5 percent from chronic headaches.

20 Jun 2007

Chemical maps hint at drug's effects on schizophrenia

Antipsychotic drugs do most of their work in the brain, but they also leave behind in the bloodstream a trail of hundreds of chemicals that may be used in the future to direct better treatment for schizophrenia and other psychiatric conditions, say Duke University Medical Center researchers.

16 May 2007

Lilly to extend patient assistance programs for Medicare patients

Eli Lilly and Company has announced that it will be extending its existing patient assistance program, LillyAnswers, through the end of this year to qualifying patients currently participating in the program, to help bridge the gap in coverage for people who need Lilly medicines, but are not yet enrolled in Medicare Part D.

11 May 2006

Olanzapine appears to lower or delay full-blown psychosis

For young people who clearly seem to be developing early signs of schizophrenia, treatment with the antipsychotic drug olanzapine appears to lower or delay the rate of conversion to full-blown psychosis, according to an article by a Yale School of Medicine researcher in the May issue of The American Journal of Psychiatry.

3 May 2006

Genes play a key role in stress response

Both nature and nurture - genetic makeup and the environment experienced through life - combine to influence health and well-being, Duke University Medical Center researchers and their colleagues have determined in four new studies.

7 Mar 2006

Study of the effects of aripiprazole, olanzapine, quetiapine and risperidone, in elderly patients with dementia

Some newer antipsychotic medications may be associated with a small increased risk of death when used to treat elderly dementia patients, psychiatrists at Johns Hopkins warn.

18 Oct 2005

Atypical antipsychotic drugs slightly increase risk for death when used in people with dementia

Atypical antipsychotic drugs seem to confer a small increased risk for death when used in people with dementia, concludes a team of researchers from the Keck School of Medicine of the University of Southern California in a meta-analysis of 15 clinical trials published in the October 19 issue of the JAMA: The Journal of the American Medical Association.

18 Oct 2005

New study details side effects of five medications that are currently used to treat people with schizophrenia

A large study funded by NIH's National Institute of Mental Health (NIMH) provides, for the first time, detailed information comparing the effectiveness and side effects of five medications - both new and older medications - that are currently used to treat people with schizophrenia.

21 Sep 2005

FDA issues public health advisory for antipsychotic drugs

The Food and Drug Administration (FDA) has issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved (i.e., “off-label”) use of certain drugs called “atypical antipsychotic drugs.”

12 Apr 2005